Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R115777 in Advanced Pancreas Cancer
NCT00005832Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2000
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in pancreatic cancer (PC), sponsored by SWOG Cancer Research Network. Primary endpoint: Survival rate at 6 months. Started Jun 2000; status: completed.
02
Drugs
tipifarnib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00005832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005832.